Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory loss? That’s the potential promise of a new class of biomark ...

JCV is a DNA polyomavirus and the primary aetiological agent of PML. Most adults carry JCV in its latent form, but the virus ...

The connection between multiple sclerosis and Epstein-Barr virus (EBV) is strengthening, according to a paper published this week in JAMA Neurology by a team of international researchers, including a ...

The connection between multiple sclerosis and Epstein-Barr virus (EBV) is strengthening, according to a paper published this ...

Smart Invert reverses the colors of the display except for images, media and some apps that use dark color styles. Linda Rossman / TNS My family is a great resource for my column topics. Usually, I ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

—A recent study found that overall pathological changes of antibody-negative primary biliary cholangitis (PBC) were slightly milder than those of antibody-positive PBC, suggesting these 2 types of PBC ...

A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumors such as triple-negative breast cancer has been developed by researchers. The University of ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Nancy Klauber-DeMore, M.D., led an MUSC team that developed a highly targeted antibody therapy that, by blocking a cancer-driving protein, slowed tumor growth, reduced metastasis and re-energized the ...